Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer

Author： Fan Alice C O'Rourke Jennifer J Praharaj Dave R Felsher Dean W

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.22, Iss.11, 2013-11, pp. : 1495-1509

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks

By Kataoka Yu

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1352-1360

Springer Publishing Company

Access to resources Recommend Favorite

The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis

By Balagula Yevgeniy

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1773-1781

Springer Publishing Company

Access to resources Recommend Favorite

Multi-Kinase Inhibitors

Current Medicinal Chemistry, Vol. 22, Iss. 6, 2015-02 ,pp. : 695-712

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy

Hematological Oncology (Electronic), Vol. 33, Iss. 2, 2015-06 ,pp. : 57-66

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo

By Han Sun-Young

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 518-523

Springer Publishing Company

Access to resources Recommend Favorite